27286-93-7

Basic information

• Product Name: gentisohydroxamic acid
• Synonyms: gentisohydroxamic acid
• CAS NO: 27286-93-7
• Molecular Formula: C₇H₇NO₄
• Molecular Weight: 169.1348
• Mol File: 27286-93-7.mol

Chemical Properties

• Melting Point: 179-181 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.571g/cm³
• Refractive Index: 1.677
• PKA: 8.44±0.41(Predicted)
• CAS DataBase Reference: gentisohydroxamic acid(CAS DataBase Reference)
• NIST Chemistry Reference: gentisohydroxamic acid(27286-93-7)
• EPA Substance Registry System: gentisohydroxamic acid(27286-93-7)

Safety Data

• Hazardous Substances Data: 27286-93-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H7NO4/c9-4-1-2-6(10)5(3-4)7(11)8-12/h1-3,9-10,12H,(H,8,11)

Upstream product

• 932380-57-9 N-(benzyloxy)-2,5-dihydroxybenzamide 

Relevant articles and documents

Inhibitors of the FEZ-1 metallo-β-lactamase

Metallo-β-lactamases (MBLs) catalyze the hydrolysis of β-lactams including penicillins, cephalosporins and carbapenems. Starting from benzohydroxamic acid (1) structure-activity studies led to the identification of selective inhibitors of the FEZ-1 MBL, e.g., 2,5-substituted benzophenone hydroxamic acid 17 has a Ki of 6.1 ± 0.7 μM against the FEZ-1 MBL but does not significantly inhibit the IMP-1, BcII, CphA or L1 MBLs.

Method of treating hemoglobinopathies

A therapeutic process for treating anemias in primates, including man, particularly those anemias of genetic origin including sickle-cell anemia, which comprises administering to an anemic primate an amount of a polyhydroxy benzoic, mandelic or phenylacetic acid derivative as specified at a dose level sufficient to increase fetal hemoglobin.

HYDROXY BENZOHYDROXAMIC ACIDS AND BENZAMIDES

Di or trihydroxybenzohydroxamic acids or N-substituted benzamides, inhibitors or ribonucleotide reductase

Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: Inhibition of ribonucleotide reductase and antitumor activity

Benzohydroxamic acids inhibit mammalian ribonucleotide reductase and exhibit antineoplastic activity in L1210 leukemic mice. Five new hydroxy- and amino-substituted benzohydroxamic acids (3,4- and 3,5-OH,3,4-NH2, 2,3,4-, and 3,4,5-OH) were prepared and tested along with 12 previously reported benzohydroxamic acids (BHA) for enzyme inhibition and antitumor activity. The most potent enzyme inhibitor in this series was 2,3,4-OH-BHA (ID50=3.5 μM), which is 140 times more potent than hydroxyurea, but its toxicity limited the antitumor activity to a 30% increase in life span of L1210 bearing mice at 125 (mg/kg) day ip for 8 days. The most effective antitumor agent in this series was 3,4-OH-BHA which prolonged the life span of L1210 bearing mice 103% at 600 (mg/kg)/day ip for 8 days.